Evidence map›Paper›PMID 42600245›Full record

ArticleVaccine2026

Clinicians' self-reported HPV vaccination recommendations for sexual and gender minority patients.

Monica L Kasting, Steven K Sutton, Megan Davish, Gwendolyn P Quinn, Kelly L Donahue, Shannon M Christy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Monica L KastingDepartment of Public Health, Purdue University, West Lafayette, IN, USA; Cancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
Steven K SuttonDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Megan DavishDepartment of Public Health, Purdue University, West Lafayette, IN, USA.
Gwendolyn P QuinnDepartment of OBGYN, New York University Grossman School of Medicine, New York, NY, USA.
Kelly L DonahueDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Shannon M ChristyDepartment of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Shannon.Christy@Moffitt.org.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

introductionThere are multiple human papillomavirus (HPV)-related disparities experienced by sexual and gender minority (SGM) populations in the United States (U.S.), including higher rates of some HPV-associated cancers, lower rates of HPV vaccination among certain subgroups, and higher rates of healthcare discrimination.

methodsWe conducted a national cross-sectional survey of U.S. primary care clinicians (physicians and advanced practice providers [APPs]) in 2024 to examine HPV vaccination recommendation practices for SGM patients. Participants responded to a series of six clinical vignettes which varied by patients' sexual orientation, sex assigned at birth, and gender identity.

resultsThe sample (n = 483) was primarily non-Hispanic (93%), White (74%), physicians (56%), and did not practice in a rural/frontier community (70%). Across the vignettes, regardless of patient characteristics, 59-69% reported they would always recommend the HPV vaccine; whereas 9-19% reported they would recommend the HPV vaccine often (50-79% of the time). The vast majority were highly consistent in recommendation likelihood across vignettes. Greater likelihood of recommending the HPV vaccine was observed for APPs versus physicians (p = 0.016), female clinicians versus males (p < 0.001), and non-Hispanic White clinicians versus other racial/ethnic groups (p = 0.006).

conclusionsIn summary, participants generally reported high likelihood of recommending the HPV vaccine, with recommendations differing very little by patient sex, sexual orientation, or gender identity.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesSexual and Gender MinoritiesVaccinationAdultCross-Sectional StudiesFemaleHuman Papillomavirus VirusesHumansMaleMiddle AgedSelf ReportSurveys and QuestionnairesUnited StatesPapillomavirus VaccinesClinician recommendationDelivery of health careHuman papillomavirusPapillomavirus vaccinesSexual and gender minorities

Identifiers

PMID42600245
PMCPMC13543079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.